Header cover image

Norwegian (OSEAX) Biotech Industry Analysis

UpdatedJan 26, 2022
DataAggregated Company Financials
Companies11
  • 7D-15.4%
  • 3M-19.1%
  • 1Y-22.6%
  • YTD-27.2%

Over the last 7 days, the Biotech industry has dropped 15%, driven by declines from every company within the industry. However, the industry is down 23% over the past year.

Industry Valuation and Performance

Has the Norwegian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Thu, 27 Jan 2022kr30.5bkr2.2bkr68.6m35.2x
Sat, 25 Dec 2021kr41.3bkr2.2bkr51.3m42.6x
Mon, 22 Nov 2021kr37.1bkr2.7bkr486.5m14.8x
Wed, 20 Oct 2021kr37.3bkr2.5bkr445.2m15.7x
Fri, 17 Sep 2021kr39.1bkr2.6bkr512.3m16x
Sun, 15 Aug 2021kr39.3bkr2.6bkr508.1m16.8x
Thu, 10 Jun 2021kr42.3bkr2.5bkr545.4m20x
Wed, 03 Mar 2021kr40.1bkr2.5bkr652.4m17.7x
Sat, 05 Dec 2020kr31.1bkr235.2m-kr1,189,469,577.0036.6x
Tue, 08 Sep 2020kr25.9bkr252.6m-kr1,172,636,276.3343.8x
Mon, 01 Jun 2020kr22.1bkr268.6m-kr1,101,468,269.7996.1x
Thu, 05 Mar 2020kr12.8bkr233.9m-kr1,101,022,953.962.5x
Sun, 08 Dec 2019kr9.5bkr189.6m-kr1,043,344,318.00n/a
Sat, 31 Aug 2019kr6.3bkr176.3m-kr1,022,520,318.00n/a
Tue, 04 Jun 2019kr5.7bkr171.1m-kr920,703,318.00n/a
Fri, 08 Mar 2019kr6.3bkr162.4m-kr917,558,318.00n/a
PE Ratio

n/a

Total Market Cap: kr6.2bTotal Earnings: -kr917,558,318.00Total Revenue: kr162.4m0%0%0%3 Year10 Year
202020212022

Current Industry PE: There are only 2 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.

Past Earnings Growth: Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 139% per year. This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Norwegian Biotech industry?

Biotech-15.36%

Industry PE: Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio of 26.2x. However analysts are expecting annual earnings decline of 16%, which is lower than the prior year's growth of 57% per year. So the market might believe that analysts are underestimating future growth or they expect the Biotech industry's earnings to deteriorate the least compared to other industries.

Forecasted Growth: Despite it being negative, analysts are least pessimistic on the Biotech industry since they expect its earnings to decline by only 16% per year over the next 5 years, which isn't as bad as the other industries. However, this is a reversal from its past annual earnings growth rate of 57% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NORD Nordakr41.00n/a
kr208.7m
7.9%PE0.5x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

BGBIO

kr17.00

BerGenBio

7D

-13.5%

1Y

-49.0%

TRVX

kr1.75

Targovax

7D

-13.7%

1Y

-79.2%